Read by QxMD icon Read

Cardiovascular Therapeutics

Raktim Kumar Ghosh, Kinjal Banerjee, Ramyashree Tummala, Somedeb Ball, Keyvan Ravakhah, Anjan Gupta
Heart failure continues to be a widely prevalent disease across the world, affecting millions of Americans annually. Acute heart failure (AHF) has a substantial effect on rising health care costs and one of the major causes of morbidity and mortality. The search for new drugs for symptom relief and to improve long term outcomes in heart failure has led to development of serelaxin, a recombinant human relaxin-2 hormone. Relaxin was discovered in pregnancy but eventually found to have a number of other physiological actions, not only in pregnancy, but also in non-pregnant women and men...
October 11, 2016: Cardiovascular Therapeutics
Rainer Zbinden, Stefanie von Felten, Bastian Wein, David Tueller, David J Kurz, Ivano Reho, Soren Galatius, Hannes Alber, David Conen, Matthias Pfisterer, Christoph Kaiser, Franz R Eberli
AIMS: The British National Institute of Clinical Excellence (NICE) guidelines recommend to use DES instead of BMS only in lesions >15mm in length or in vessels < 3mm in diameter. We analysed the impact of stent length and stent diameter on ISR in the BASKET-PROVE study population and evaluated the cost-effectiveness of DES compared to BMS. METHODS/RESULTS: The BASKET-PROVE trial compared DES vs. BMS in large coronary arteries (≥3mm). We calculated incremental cost-effectiveness ratios (ICERs) and cost-effectiveness acceptability curves with regard to quality-adjusted life years (QALYs) gained and target lesion revascularisations (TLRs) avoided...
September 23, 2016: Cardiovascular Therapeutics
Mingming Ren, Tao Wang, Lei Huang, Xiaoqiang Ye, Zhifeng Xv, Chun Ouyang, Zhen Han
AIM: Accumulating evidence showed that transient receptor potential channels play an important role in the regulation of cardiomyocyte differentiation. The vanilloid receptor 1 (VR1) is a member of the transient receptor channel super family and is expressed in cardiomyocytes. However, its function in cardiomyocytes remains unclear. METHODS: Herein, the aim of this study was to investigate the functional role of VR1 in the cardiomyocyte differentiation of bone marrow-derived mesenchymal stem cells (BMSCs), and to elucidate the potential molecular mechanisms...
September 23, 2016: Cardiovascular Therapeutics
Jinhua Zhang, Lihong Tian, Jinlong Huang, Sihan Huang, Tingting Chai, Jianzhen Shen
AIM: To assess the effect of Cytochrome P450 2C9 (CYP2C9) gene polymorphism on pediatric warfarin maintenance dosage requirement. METHODS: A previously developed search strategy was conducted in PubMed, EMBASE, and the Cochrane Library. Eligible studies published prior to January 27, 2016, were identified and compared against strict inclusion/exclusion criteria. Required data were extracted, and researchers were consulted for additional data if needed. Review Manager Version 5...
September 23, 2016: Cardiovascular Therapeutics
Yukio Mizuguchi, Hiroki Shibutani, Sho Hashimoto, Takeshi Yamada, Norimasa Taniguchi, Shunsuke Nakajima, Tetsuya Hata, Akihiko Takahashi
AIM: The influence of the time of arrival at the hospital on the door-to-device (DTD) time has been investigated; however, the influence on the onset-to-device (OTD) time is unclear in ST-segment elevation myocardial infarction (STEMI) patients. The aim of this study was to investigate the relationship between the time of arrival at the hospital and the OTD time in STEMI patients. METHODS: We evaluated 377 STEMI patients who underwent primary percutaneous coronary intervention (pPCI) between January 2008 and December 2014...
September 8, 2016: Cardiovascular Therapeutics
Nikos Papageorgiou, Alexandros Briasoulis, George Lazaros, Massimo Imazio, Dimitris Tousoulis
AIMS: Colchicine has been suggested to be beneficial in preventing recurrent pericarditis. The goal of this study was to review all randomized controlled trials that assess the use of colchicine for the prevention and treatment of cardiac diseases. METHODS: We performed a meta-analysis of the effects of colchicine on pericarditis, post-pericardiotomy syndrome and post-procedural atrial fibrillation recurrence, in-stent restenosis, gastrointestinal adverse effects and treatment discontinuation rates...
August 31, 2016: Cardiovascular Therapeutics
Chun-Wei Liu, Fan Yang, Shi-Zhao Cheng, Yue Liu, Liang-Hui Wan, Hong-Liang Cong
AIMS: Glycogen synthase kinase-3β (GSK-3β) and mitochondrial permeability transition pore (mPTP) play an important role in myocardial ischemia-reperfusion injury. The aim of this study is to investigate whether postconditioning with rosuvastatin is able to reduce myocardial ischemia-reperfusion injury and clarify the potential mechanisms. METHODS: Isolated rat hearts underwent 30 min of ischemia and 60 min of reperfusion in the presence or absence of rosuvastatin (1-50 nM)...
August 31, 2016: Cardiovascular Therapeutics
Hong-Hui Yang, Yan Chen, Chuan-Yu Gao
OBJECTIVE: To investigate the correlations of three P2Y12 receptor (P2Y12R) gene polymorphisms (rs7428575 T>G, rs2046934 C>T and rs3732759 A>G) with susceptibility to coronary artery disease (CHD) and clinical efficacy of clopidogrel treatment for CHD. METHODS: From May 2014 to May 2015, 178 CHD patients (the case group) and 182 healthy controls (the control group) were selected from our hospital. The platelet-rich plasma (PRP) turbidimetry was used to measure the rate of adenosine diphosphate (ADP)-induced platelet aggregation before and after clopidogrel treatment...
August 27, 2016: Cardiovascular Therapeutics
Fredrik Björck, E K Agnes, Lars Johansson, Anders Själander
BACKGROUND AND AIM: Warfarin treatment discontinuation is significant among patients with atrial fibrillation (AF). Studies mainly focused on whether the proportion of warfarin persistence and discontinuation are clinically appropriate are absent. This study evaluates warfarin persistence with focus on predictors for, and reasons to, warfarin discontinuation in AF patients. METHODS: From the national quality register AuriculA, all AF patients in Sundsvall, Sweden, on warfarin treatment on January first, 2010 were included...
August 27, 2016: Cardiovascular Therapeutics
Erru Yang, Michael Stokes, Saga Johansson, Carl Mellström, Elizabeth Magnuson, David J Cohen, Phillip Hunt
OBJECTIVES: Longitudinal data are limited regarding outcomes and costs beyond one year after acute myocardial infarction (MI) among elderly (≥65 years old) United States patients. This study examined long-term outcomes and healthcare costs among elderly MI survivors. METHODS: .Retrospective analysis of 2002-2009 Medicare healthcare claims (5% random sample). Patients were ≥65 years old and survived ≥1 year without recurrent MI after MI hospitalization. Mortality, incidence of hospitalizations for stroke, major bleeding, MI, a composite endpoint (death, MI or stroke), and non-pharmacy healthcare costs were determined...
August 26, 2016: Cardiovascular Therapeutics
Wei Xin, Shuhua Mi, Zhiqin Lin
AIMS: Effect of allopurinol on flow-mediated dilation (FMD), an index of endothelial function in humans, remains inconsistent. We performed a meta-analysis to determine whether allopurinol therapy could improve FMD. METHODS: Human intervention studies were identified by systematic searches of Medline, Embase, Cochrane's library and references of related reviews and studies. A random-effect model was applied to estimate the pooled results. RESULTS: Ten randomized controlled trials with 594 subjects of cardiovascular risks were included...
August 20, 2016: Cardiovascular Therapeutics
Juliana C N Chan, Alice P S Kong, Weihang Bao, Rana Fayyad, Rachel Laskey
Data on statin safety in Asian patients are limited compared with evidence from Western populations AIM: This study assessed atorvastatin safety among Asian patients enrolled in 58 randomized clinical trials METHODS: Data from 52 short-term trials (median exposure 4-72 weeks) and 6 long-term cardiovascular outcomes trials (median exposure 3.1-4.9 years) conducted across the atorvastatin 10-80-mg dose range were analyzed retrospectively to assess the incidence of safety end points RESULTS: A total of 77,952 patients were identified (49,974 received atorvastatin), among whom 3191 were Asian (2519 received atorvastatin)...
August 13, 2016: Cardiovascular Therapeutics
Anthony S Gunnell, Joseph Hung, Matthew W Knuiman, Lee Nedkoff, Malcolm Gillies, Elizabeth Geelhoed, Michael St Hobbs, Judith M Katzenellenbogen, Jamie M Rankin, Michael Ortiz, Tom G Briffa, Frank M Sanfilippo
AIM: Describe the dispensing patterns for guideline-recommended medications during 2008 in people with acute coronary syndrome (ACS) and how dispensing varies by gender and time since last ACS hospitalisation. METHOD: A descriptive cohort spanning 20 years of people alive post ACS in 2008. We extracted all ACS hospitalisations and deaths in Western Australia (1989-2008), and all person-linked Pharmaceutical Benefits Scheme claims nationally for 2008. Participants were 23,642 men and women (36...
August 4, 2016: Cardiovascular Therapeutics
Kathleen A Packard, Daniel E Hilleman
Suboptimal adherence to medications taken chronically for secondary prevention of cardiovascular disease (CVD, e.g., aspirin) continues to burden the healthcare system despite the well-established benefits of prevention. We conducted a literature search to examine patient adherence to medications for secondary prevention of CVD-as evaluated by prescription refill data, electronic medication monitors, pill counts, and physiologic markers-to better identify an unmet need for measures to improve patient adherence to these therapies METHODS: English-language articles were obtained from the PubMed database using the following key words or combinations thereof: "adherence," "compliance," "secondary prevention," and "cardiovascular disease...
July 30, 2016: Cardiovascular Therapeutics
Kyung-Jin Kim, Sang-Hyun Kim, Young Won Yoon, Seung-Woon Rha, Soon-Jun Hong, Choong-Hwan Kwak, Weon Kim, Chang-Wook Nam, Moo-Yong Rhee, Tae-Ho Park, Taek-Jong Hong, Sungha Park, Youngkeun Ahn, Namho Lee, Hui-Kyung Jeon, Dong-Woon Jeon, Kyoo-Rok Han, Keon-Woong Moon, In-Ho Chae, Hyo-Soo Kim
AIM: We aimed to compare the effects of fixed-dose combinations of ezetimibe plus rosuvastatin to rosuvastatin alone in patients with primary hypercholesterolemia, including a subgroup analysis of patients with diabetes mellitus (DM) or metabolic syndrome (MetS). METHOD: This multicenter eight-week randomized double-blind phase III study evaluated the safety and efficacy of fixed-dose combinations of ezetimibe 10 mg plus rosuvastatin, compared with rosuvastatin alone in patients with primary hypercholesterolemia...
October 2016: Cardiovascular Therapeutics
Sadegh Ali-Hassan-Sayegh, Seyed Jalil Mirhosseini, Mahbube Tahernejad, Parisa Mahdavi, Azadeh Shahidzadeh, Ali Akbar Karimi-Bondarabadi, Ali-Mohammad Dehghan, Elham Rahimizadeh, Fatemeh Haddad, Zahra Ghodratipour, Zahra Sarrafan-Chaharsoughi, Arezoo Shahidzadeh, Azam Ghanei, Mohammadreza Lotfaliani, Mohamed Zeriouh, Alexander Weymann, Aron-Frederik Popov, Anton Sabashnikov
This systematic review with meta-analysis sought to determine the strength of evidence in terms of the impact of common antioxidant supplementations, such as N-acetylcysteine (NAC), vitamin C, and polyunsaturated fatty acids (PUFA) on perioperative outcomes after cardiac surgery with particular focus on the incidence of atrial fibrillation (AF) and acute kidney injury (AKI) with associated mortality. A total of 29 trials were identified that reported incidence of AF and 17 trials that reported incidence of AKI...
October 2016: Cardiovascular Therapeutics
Huikuan Gao, Fei Hou, Ruiqing Dong, Zefeng Wang, Can Zhao, Wurina Tang, Yongquan Wu
INTRODUCTION: Cardiac cell apoptosis plays a crucial role in the progression of diabetic cardiomyopathy. Recent studies have shown that fasudil, a Rho-kinase (ROCK) inhibitor, inhibits cardiac cell apoptosis; however, the underlying mechanism remains unclear. AIM: This study aimed to investigate whether fasudil protects H9c2 cells from high glucose-induced apoptosis via activation of autophagy. METHODS: Rat cardiomyocyte H9c2 cells were treated with high glucose and used as a diabetic cardiomyopathy model...
October 2016: Cardiovascular Therapeutics
Min Ren, Yujie Liu, Huiya Zhao, Shixia Dong, Zhonghui Jiang, Keting Li, Jiawei Tian
INTRODUCTION: Effects of ischemic postconditioning (IPostC) and adenosine triphosphate (ATP)-mediated pharmacologic postconditioning (ATP-PPostC) on cardiac function were evaluated by speckle tracking imaging (STI)-based echocardiography. AIMS: A myocardial I/R model was induced in rabbits by reversible ligation of the left ventricular branch of coronary artery. Rabbits were randomized into three groups: ischemia and reperfusion (IR) (no further intervention), IPostC, and ATP-PPostC groups...
October 2016: Cardiovascular Therapeutics
Kai Xu, Xinming Liu, Yi Li, Yunuo Wang, Hongyun Zang, Liang Guo, Yuan Wang, Wei Zhao, Xiaozeng Wang, Yaling Han
OBJECTIVES: To investigate safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation. BACKGROUND: Certain number of patients has high residual platelet reactivity on clopidogrel after coronary intervention, and their risk of thrombotic events is high. METHOD: In this prospective, randomized trial conducted in four Chinese sites, 350 patients with high on-treatment platelet reactivity (HPR, defined as platelet aggregation >65%) were randomized by the ratio of 1:3:3 to: group A, clopidogrel 75 mg/d for 1 year (n=50); group B, clopidogrel 150 mg/d for 30 days followed by 75 mg/d until 1 year (n=150); or group C, policosanol 40 mg/d for 6 month and clopidogrel 75 mg/d for 1 year (n=150)...
October 2016: Cardiovascular Therapeutics
Lewis E Holmes, Rohan Gupta, Saissan Rajendran, John Luu, John K French, Craig P Juergens
AIMS: To compare three glycoprotein IIb/IIIa receptor antagonists (GPIs) in terms of platelet inhibition and major adverse cardiac events (MACEs), and assess the rate of bleeding and MACEs between GPIs and coadministered P2Y12 agents. METHODS: Eighty-three acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) with planned GPI use were randomized to receive high-dose bolus tirofiban, double-bolus eptifibatide, or abciximab followed by a 12-hour infusion...
October 2016: Cardiovascular Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"